Telitacicept for Antibody–Mediated Rejection in Kidney Transplantation: A Retrospective Real–World Study

Background Antibody–mediated rejection (AMR) remains a leading cause of late kidney allograft loss due to a lack of effective therapies. Telitacicept, a recombinant TACI–Ig fusion protein neutralizing B–lymphocyte stimulator (BLyS) and a proliferation–inducing ligand (APRIL), showed efficacy in antibody–mediated autoimmune disorders, but its role in AMR remains unexplored. Methods In this single–center, retrospective, real–world study, ten kidney transplant recipients with biopsy–proven active or chronic active AMR received telitacicept for ≥ 6 months plus standard antirejection therapy and underwent follow–up biopsy within one year. Outcomes included allograft function, proteinuria, donor–specific antibody (DSA) levels, and Banff scores. Results Over a follow–up lasting more than two years, allograft function remained stable (estimated glomerular filtration rate [eGFR] change within ±20%) in 70% (7/10), with annualized eGFR slopes ranging from −3.59 to +9.34 mL/min/1.73 m²/year among responders. Four of six patients with baseline proteinuria (>1 g/24h) had sustained reductions, and serum immunoglobulins (IgG, IgM, IgA) declined significantly (P < 0.05). Circulating human leukocyte antigen (HLA) and DSA levels generally decreased at first follow–up, with variable rebound after discontinuation. Follow-up biopsies showed reductions in intimal arteritis (v), peritubular capillaritis (ptc), and C4d deposition. Five patients no longer met Banff AMR criteria. Residual microvascular inflammation persisted in four, and borderline T-cell–mediated rejection features occurred in one. Microvascular inflammation score decreased numerically (3.5 to 2.0; P = 0.063), and chronic lesions remained largely stable. Infectious complications occurred but resolved with treatment. Conclusion In this small, uncontrolled cohort, telitacicept–based therapy was associated with heterogeneous clinical and histopathological changes, warranting prospective controlled trials.

Authors

Institutions

Publication Details

Journal
Journal of Nephrology
Published
2026-11-21
DOI
https://doi.org/10.1093/joneph/aajag284
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Telitacicept for Antibody–Mediated Rejection in Kidney Transplantation: A Retrospective Real–World Study

Qianqian Ye, 朱碧松, 黄昌浩, Meng Meng et al.
Journal of Nephrology
Renal Transplantation Outcomes and Treatments
article

Telitacicept for Antibody–Mediated Rejection in Kidney Transplantation: A Retrospective Real–World Study

Qianqian Ye, 朱碧松, 黄昌浩, Meng Meng, Wei Lin, Weiyuan Wang, Peng Jin, Bo Yang, Xiang Ding, Lielin Wu
article en

Abstract

Background Antibody–mediated rejection (AMR) remains a leading cause of late kidney allograft loss due to a lack of effective therapies. Telitacicept, a recombinant TACI–Ig fusion protein neutralizing B–lymphocyte stimulator (BLyS) and a proliferation–inducing ligand (APRIL), showed efficacy in antibody–mediated autoimmune disorders, but its role in AMR remains unexplored. Methods In this single–center, retrospective, real–world study, ten kidney transplant recipients with biopsy–proven active or chronic active AMR received telitacicept for ≥ 6 months plus standard antirejection therapy and underwent follow–up biopsy within one year. Outcomes included allograft function, proteinuria, donor–specific antibody (DSA) levels, and Banff scores. Results Over a follow–up lasting more than two years, allograft function remained stable (estimated glomerular filtration rate [eGFR] change within ±20%) in 70% (7/10), with annualized eGFR slopes ranging from −3.59 to +9.34 mL/min/1.73 m²/year among responders. Four of six patients with baseline proteinuria (>1 g/24h) had sustained reductions, and serum immunoglobulins (IgG, IgM, IgA) declined significantly (P < 0.05). Circulating human leukocyte antigen (HLA) and DSA levels generally decreased at first follow–up, with variable rebound after discontinuation. Follow-up biopsies showed reductions in intimal arteritis (v), peritubular capillaritis (ptc), and C4d deposition. Five patients no longer met Banff AMR criteria. Residual microvascular inflammation persisted in four, and borderline T-cell–mediated rejection features occurred in one. Microvascular inflammation score decreased numerically (3.5 to 2.0; P = 0.063), and chronic lesions remained largely stable. Infectious complications occurred but resolved with treatment. Conclusion In this small, uncontrolled cohort, telitacicept–based therapy was associated with heterogeneous clinical and histopathological changes, warranting prospective controlled trials.

Journal of Nephrology
Central South University (CN), Hunan Cancer Hospital (CN), Xiangya Hospital Central South University (CN)
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon